In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Bayer BAY x1351

Executive Summary

Bayer BAY x1351: Preliminary analysis of data from Phase III trials of the anti-TNF monoclonal antibody does not show superiority to placebo in reducing mortality in septic shock patients. Bayer will await full analyses of the data, which it plans to present in late June and autumn to scientific meetings, before making a decision on continuing development. The company has invested in a $100 mil. biotechnology facility in Berkeley, Calif. to supply the product ("The Pink Sheet" April 14, T&G-5)...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts